Boston, Mass. — Massachusetts Eye and Ear made medical history on Tuesday by performing the first post-FDA approval gene therapy for patients with a form of inherited blindness. The occasion marks the beginning of a new era in medicine, as it is the first time any FDA-approved gene therapy has been given to a patient for any inherited disease.
The treatment, commercially identified as Luxturna, was developed by Spark Therapeutics and ...
Joseph Arboleda-Velasquez, MD, PhD, received a grant from the National Institute of Neurological Disorders and Stroke and National Institute of Aging/National Institutes of Health in the amount of $1,016,301 over five years for his project, "Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant Mice."
Jason Comander, MD, PhD, received a Foundation Fighting Blindness Enhanced Career Development Award in the amount of $510,000 over three years.
Meredith Gregory-Ksander, PhD, received a grant from ONL Therapeutics in the amount of $59,739 over one year to determine whether treatment with a Fas inhibitor can prevent neuroinflammation and the death of RCGs in a mouse model of glaucoma.
On October 7th and 8th, Jason Comander, MD, PhD, andLeo Kim, MD, PhD, participated in the Alliance for Eye and Vision Research (AEVR) Emerging Vision Scientists Program. This program allows scientists to meet with members of Congress to discuss the importance of vision research in the continuing fight to prevent blindness.
